KFDA approved Yuhan's anti-peptic drug Revanex tab.

Published: 2005-09-22 07:00:00

Updated: 2005-09-22 07:00:00

Yuhan said that as of Sept. 15 the new drug named Revanex (Revaprazan) has been completely registered to the KFDA as an anti-duodenal ulcer drug, which will be of No. 9 of Korean new drug.

Revanex has been developed at about 40 billion won of investment since 1994. It's application for the KFD...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK